• LAST PRICE
    0.0750
  • TODAY'S CHANGE (%)
    Trending Down-0.0050 (-6.2500%)
  • Bid / Lots
    0.0750/ 25
  • Ask / Lots
    0.0800/ 9
  • Open / Previous Close
    0.0800 / 0.0800
  • Day Range
    Low 0.0750
    High 0.0800
  • 52 Week Range
    Low 0.0600
    High 0.1650
  • Volume
    12,000
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.08
TimeVolumeAGN
09:32 ET10000.08
10:58 ET110000.075
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
CanadaAGN
Algernon Pharmaceuticals Inc
2.0M
-0.4x
---
CanadaPSYB.H
PsyBio Therapeutics Corp
1.3M
-0.3x
---
CanadaTMED
EGF Theramed Health Corp
2.3M
-9.2x
---
CanadaMYND
MYND Life Sciences Inc
1.8M
-6.3x
---
CanadaNIRV
Nirvana Life Sciences Inc
2.5M
-2.3x
---
CanadaHEAL
Restart Life Sciences Corp
1.5M
-1.9x
---
As of 2024-11-22

Company Information

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

Contact Information

Headquarters
400 - 601 WEST BROADWAYVANCOUVER, BC, Canada V5Z 4C2
Phone
604-398-4175
Fax
604-646-1553

Executives

No data available

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.0M
Revenue (TTM)
$0.00
Shares Outstanding
27.3M
Algernon Pharmaceuticals Inc does not pay a dividend.
Beta
-0.35
EPS
$-0.19
Book Value
$0.09
P/E Ratio
-0.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.